**Local organizers:**
Manel Juan. Immunology. CDB. Hospital Clínic.
Julio Delgado. Hematology. ICMHO. Hospital Clínic.
Susana Rives. Pediatric Hematology. Hospital San Joan de Déu.
Anna Boronat. Institut d’Investigacions Biomèdiques August Pi i Sunyer.

Instituto de Salud Carlos III (ISCIII) & Fondo Europeo de Desarrollo Regional (FEDER):
PI13/00676; PIE13/00033 ; PICIS14/00122. MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD: SAF2014-53563-REDT (REINCA)

**Main sponsorship:**

![Novartis Logo](image)

**Secretary, registration and information:**
Eva Palacios
Tel. +34.93.203.13.18
evapalacios@academia.cat

**Registrations:** [http://www.cart19.org](http://www.cart19.org)

Records strictly limited to the capacity of the auditorium!!
09:00 – 09:05 Welcome and presentation of the symposium.
   Dr. Josep M Piqué (General Director of Hospital Clinic) / Dr. Àurea Mira (Director of CDB) / Dr. Manel Juan (Chairman)

09:05 – 10:30 **Table 1: B-cell lymphoproliferative disorders (BLD) and CD19**
   Dr. Josep Maria Ribera / Dr. Jordi Yagüe
   09:10 – 09:30 CD19 as a key molecule for B-cells.
   Dr. Pablo Engel, Univ. Barcelona – IDIBAPS, Barcelona
   Dr. Armando López-Guillermo, Hospital Clinic – IDIBAPS, Barcelona
   09:50 – 10:05 Present and future of Chronic Lymphocytic Leukemia (CLL) clinical management.
   Dr. Julio Delgado, Hospital Clinic - IDIBAPS, Barcelona.
   10:05 – 10:20 Present and future of pediatric Acute Lymphoblastic Leukemia (ALL) clinical management.
   Dr. Susana Rives, Hospital Sant Joan de Deu, Barcelona,
   10:20 – 10:30 **Questions and discussion.**

10:30 – 10:45 Coffee break

10:45 – 12:45 **Table 2: Immunological bases of CART19 treatment as a real Cell Adoptive Cancer ImmunoTherapy (CACIT).**
   Dr. Manel Juan / Dr. Pablo Menéndez
   10:45 – 11:05 Overview CACIT in Cancer.
   Dr. Daniel Benítez, CIBERehd, Barcelona, Spain
   11:05 – 11:40 CACIT from hematologic diseases to solid tumors.
   Dr. James N Kochenderfer, NCI, Washington, USA.
   11:40 – 12:15 CART19 present and future.
   Dr. Carl H June, UPenn, Philadelphia, USA.
   12:15 – 12:45 **Questions and discussion.**

12:45 – 14:00 **Working lunch time**

14:00 – 16:00 **Table 3: Developing a T-cell immunotherapy trial**
   Dr. Josep Mº Canals / Dr. Javier Briones
   14:00 – 14:20 Design and preclinical evaluation of CART therapies.
   Dr. Sònia Guedan, UPenn, Philadelphia, USA - IDIBELL, L'Hospitalet.
   14:20 – 14:40 How to develop and monitor a CART19 trial in Spain.
   Dr. Manel Juan, Hospital Clinic; Hospital Clinic – IDIBAPS, Barcelona
   14:40 – 15:10 Regulatory aspects for cell immunotherapy in Europe.
   Dr. Estève Trias, Adv Therapy Hospital Clinic – Banc Sang i Treuixts, Barcelona.
   15:10 – 15:40 Investigator Initiated Clinical Trials (IIT) of Advanced Therapy Medicinal Products in Spain.
   Dr. Felipe Prosper, Director of Hematology and Cell Therapy. Universidad de Navarra. Spain.
   15:40 – 16:00 **Questions and discussion.**

16:00 – 16:15 Coffee break

16:15 – 19:00 **Table 4: Clinical management of CART19 patients**
   Dr. Julio Delgado / Dr. Susana Rives
   16:15 – 16:50 Treating adults with CART19
   Dr. David Porter, UPenn, Philadelphia, USA
   16:50 – 17:25 Treating children with CART19
   Dr. Stephan A Grupp, Children’s Hospital of Philadelphia, Philadelphia, USA
   17:25 – 18:00 CARs and Armored CARs.
   Dr. Renier Brentjens, Memorial Sloan Kettering Cancer Center, NY, USA
   18:00 – 18:35 Experience of developing an European CAR trial
   Dr. Martin Pule, UCL Institute of Child Health Great Ormond Street Hospital
   18:35 – 19:00 **Questions and discussion.**

19:00 – 19:15 Conclusions and closing event
   Dr. Francesc Cardellach (Dean of School of Medicine Univ.Barcelona) / Dr. Josep M Campistol (Medical Director) / Dr. Manel Juan (Chairman)